InsidersTradesSigma
Total declarations
Company
▲ Purchases (8 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
8
Disclosed sells
1
T+90 hit rate
43%
T+90 mean return
+0.4%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Silva Francisco, Vice-Président. Director active across 1 company, notably BioRestorative Therapies, Inc.. Cumulatively, 16 disclosures have been published. Split: 8 buys · 1 sell. Total volume traded: €81k. History available since 16 November 2021. The latest transaction was disclosed on 6 October 2025 (Attribution). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Silva Francisco
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations16 total
11,719 shares@ US$1.6011.3% of flowComon StockSEC:0001021771-25-000141:0
476 shares@ US$1.130.3% of flowCommon StockSEC:0001021771-24-000091:0
Canonical exit: 7 Jul 2024 (T+90)
17,193 shares@ US$1.3912.8% of flowCommon StockSEC:0001021771-24-000079:0
4,954 shares@ US$2.225.9% of flowCommon StockSEC:0001021771-23-000086:0
Canonical exit: 29 Nov 2023 (T+90)
747 shares@ US$3.561.4% of flowCommon StockSEC:0001021771-23-000034:0
Canonical exit: 29 Jun 2023 (T+90)
6,729 shares@ US$2.9210.7% of flowCommon StockSEC:0001021771-23-000028:0
374 shares@ US$2.990.6% of flowCommon StockSEC:0001567619-23-003891:0
943 shares@ US$2.61621.4% of flowCommon StockSEC:0001567619-22-020707:0
Canonical exit: 19 Feb 2023 (T+90)
725 shares@ US$3.38841.5% of flowCommon StockSEC:0001567619-22-018437:0
Canonical exit: 10 Jan 2023 (T+90)
806 shares@ US$3.68861.8% of flowCommon StockSEC:0001567619-22-018424:0
Canonical exit: 9 Jan 2023 (T+90)
3,958 shares@ US$3.3887.8% of flowCommon StockSEC:0001567619-22-017246:0
263 shares@ US$3.77740.7% of flowCommon StockSEC:0001567619-22-012893:0
565 shares@ US$4.64931.7% of flowCommon StockSEC:0001567619-22-012496:0
12,438 sharesCommon StockSEC:0001567619-22-007349:0
4,000 shares@ US$6.656516.5% of flowCommon StockSEC:0001567619-21-020924:0
Canonical exit: 17 Feb 2022 (T+90)
3,826 shares@ US$6.8316.2% of flowCommon StockSEC:0001567619-21-020585:0
Canonical exit: 14 Feb 2022 (T+90)
16 of 16 declarations
About Silva Francisco
Silva Francisco is Vice-Président and VP of Research and Development at BioRestorative Therapies, Inc. He has 16 filings in total, and across the sampled recent filings from 2021-11-16 to 2025-10-20, buys amount to EUR 67,470 and sells to EUR 13,448, with Acquisition as the modal transaction nature.
